Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Revenue (2016 - 2025)

Ani Pharmaceuticals' Revenue history spans 16 years, with the latest figure at $247.1 million for Q4 2025.

  • For Q4 2025, Revenue rose 29.64% year-over-year to $247.1 million; the TTM value through Dec 2025 reached $883.4 million, up 43.78%, while the annual FY2025 figure was $883.4 million, 43.78% up from the prior year.
  • Revenue for Q4 2025 was $247.1 million at Ani Pharmaceuticals, up from $227.8 million in the prior quarter.
  • Across five years, Revenue topped out at $247.1 million in Q4 2025 and bottomed at $11.2 million in Q1 2021.
  • The 5-year median for Revenue is $124.1 million (2023), against an average of $123.7 million.
  • The largest annual shift saw Revenue plummeted 77.5% in 2021 before it skyrocketed 475.69% in 2022.
  • A 5-year view of Revenue shows it stood at $60.9 million in 2021, then soared by 54.66% to $94.2 million in 2022, then soared by 39.71% to $131.7 million in 2023, then skyrocketed by 44.75% to $190.6 million in 2024, then grew by 29.64% to $247.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Revenue are $247.1 million (Q4 2025), $227.8 million (Q3 2025), and $211.4 million (Q2 2025).